TRX-4 TolerRx Inc

IDrugs

Volumn 9, Issue 4, 2006, Pages 283-291

  Brown, William M ^a  

^a Paddock Laboratories Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFM 15; ANTIIDIOTYPIC ANTIBODY; AZATHIOPRINE; CD3 ANTIBODY; CD3 ANTIGEN; IMMUNOSUPPRESSIVE AGENT; INSULIN; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD3; OKT 3; PLACEBO; Q T3; RECOMBINANT YTH 12.5; TRX 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASILIZUMAB;

ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIGENICITY; ARTHRALGIA; ARTICLE; B LYMPHOCYTE; CLINICAL TRIAL; COMPETITIVE INHIBITION; CROHN DISEASE; CYTOKINE RELEASE; CYTOKINE SYNDROME; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG PURIFICATION; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERANCE; EARLY INTERVENTION; EXPRESSION VECTOR; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GRAFT REJECTION; HUMAN; HYPOGLYCEMIA; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY TRANSPLANTATION; LYMPHOCYTE FUNCTION; MONOTHERAPY; MYALGIA; NONHUMAN; PATENT; PSORIASIS; RECEPTOR BINDING; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; T LYMPHOCYTE; ULCERATIVE COLITIS; VOMITING;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DIABETES MELLITUS, TYPE 1; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; PATENTS; PSORIASIS; TREATMENT OUTCOME;

EID: 33646032395     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (85)

1. 317752 BTG licenses anti-CD3 antibody technology to LeukoSite Inc. BTG International Ltd PRESS RELEASE 1999 March 10
2. 392555 Millennium Pharmaceuticals Inc - Product Pipeline. Millennium Pharmaceuticals Inc COMPANY WORLD WIDE WEB SITE 2000 December 07
3. 413551 American Diabetes Association's - 61st Scientific Sessions (Part IV) - OVERNIGHT REPORT, Philadelphia, PA, USA, 22-26 June 2001. Patterson C IDDB MEETING REPORT 2001 June 22-26
4. 414047 Treatment with anti-CD3 monoclonal antibody (mAb) hOKT3γ1(Ala-Ala) improves glycemic control during the first year of type 1 diabetes mellitus (T1DM). Herold KC, Hagopian WJ, AugerPoumain-Ruiz E, Tailor L, Febres G, Harlan D, Bluestone JA DIABETES 2001 50 Suppl 6 Abs 138-OR
5. 445501 The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Bolt S, Routledge E, Lloyd I, Chatenoud L, Pope H, Gorman SD, Clark M, Waldmann H EUR J IMMUNOL 1993 23 2 403-411
6. 445504 A humanized monovalent CD3 antibody which can activate homologous complement. Routledge EG, Lloyd I, Gorman SO, Clark M, Waldmann H EUR J IMMUNOL 1991 21 11 2717-2725
7. 454343 Novel immune-based therapies for psoriasis. Kirby B, Griffiths CEM BR J DERMATOL 2002 146 4 546-551
8. 463420 Insulin-dependent diabetes mellitus as an autoimmune disease. Bach JF ENDOCR REV 1994 16 4 516-542
9. 463619 Peptides derived from murine insulin are diabetogenic in both rats and mice, but the disease-inducing epitopes are different: Evidence against a common environmental cross-reactivity in the pathogenicity of type 1 diabetes. Heath VL, Hutchings P, Fowell DJ, Cooke A, Mason DW DIABETES 1999 48 11 2157-2165
10. 478326 Product pipeline and TRX-3 antibody program overview. TolerRx Inc COMPANY WORLD WIDE WEB SITE 2003 February 10
11. 523625 New Trends in Immunosuppression - Sixth International Congress, New Drug Candidates, Salzburg, Austria, 5-8 February 2004. von Herrath M IDDB MEETING REPORT 2004 February 5-8
12. 551951 TolerRx begins TRX-4 phase I study for psoriasis. TolerRx Inc PRESS RELEASE 2004 August 02
13. 592061 TolerRx raises $31 million in series D financing. TolerRx Inc PRESS RELEASE 2005 March 29
14. 593126 TolerRx acquires anti-CD3 technology from Diabetogen. TolerRx Inc PRESS RELEASE 2005 April 04
15. 601648 Serono and NovImmune to collaborate in development of two novel treatments for autoimmune diseases. Serono SA PRESS RELEASE 2005 May 17
16. 609227 TolerRx's diabetes drug shows clinical promise. TolerRx Inc PRESS RELEASE 2005 June 23
17. 609291 Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, Gorus F, Goldman M, Walter M, Candon S, Schandene L et al N ENGL J MED 2005 352 25 2598-2608
18. 616224 PDL Announces Strong Second Quarter 2005 Financial Results. Protein Design Labs Inc PRESS RELEASE 2005 August 04
19. 620988 Product pipeline. TolerRx Inc COMPANY WORLD WIDE WEB SITE 2005 September 02
20. 630882 Regulatory T cells: Development, function and role in autoimmunity. Lan RY, Ansari AA, Lian ZX, Gershwin ME AUTOIMMUNITY REV 2005 4 6 351-363
21. 637721 Abbott to make TolerRx's antibody for diabetes and psoriasis. TolerRx Inc PRESS RELEASE 2005 November 29
22. 638057 Biocon - Symbiosis Partnering for Life. Biocon Ltd ANNUAL REPORT 2005 March 31
23. 638291 TRX4 antibody. TolerRx Inc COMPANY WORLD WIDE WEB SITE 2005 December 01
24. 638663 Profile and pipeline. Affimed Therapeutics AG COMPANY WORLD WIDE WEB SITE 2005 December 05 http://www.affimed.com/
25. 639132 TolerRx initiates three clinical trials in autoimmune indications. TolerRx Inc PRESS RELEASE 2005 December 07
26. 645630 TRX-4. TolerRx Inc COMPANY COMMUNICATION 2006 January 17
27. 645732 Preliminary results for the year ended 31 March 2004. BTG plc COMPANY PRESENTATION 2004 March 31
28. 645822 Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. Friend PJ, Hale G, Chatenoud L, Rebello P, Bradley J, Thiru S, Phillips JM, Waldmann H TRANSPLANTATION 1999 68 11 1632-1637
29. 657630 Sparing of first dose effect of monovalent anti-CD3 antibody used in allograft rejection is associated with diminished release of pro-inflammatory cytokines. Abbs IC, Clark M, Waldmann H, Chatenoud L, Koffman CG, Sacks SH THER IMMUNOL 1994 16 325-331.
30. 650222 TolerRx's TRX-4 granted US Orphan status for type 1 diabetes. TolerRx Inc PRESS RELEASE 2006 February 14
31. 651233 Targeting T lymphocytes for immune monitoring and intervention in autoimmune diabetes. Mallone R, Nepom GT AM J THER 2005 12 6 534-550
32. 651234 Therapeutic targets for the prevention of type 1 diabetes mellitus. Singh N, Palmer JP CURR DRUG TARGETS IMMUNE ENDOCR METAB DISORD 2005 5 2 227-236
33. 651235 Treatment of type 1 diabetes with anti-T-cell agents: From T-cell depletion to T-cell regulation. Glandt M, Herold KC CURR DIABETES REP 2004 4 4 291-297
34. 651238 Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Chatenoud L, Thervet E, Primo J, Bach J-F PROC NATL ACAD SCI USA 1994 93 1 123-127
35. 651252 Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus. Eisenbarth GS, Srikanta S, Jackson R, Rabinowe S, Dolinar R, Aoki T, Morris MA DIABETES RES 1985 2 6 271-276
36. 651254 Cyclosporine in recent onset type I diabetes mellitus. Effects on islet β cell function. Miami Cyclosporine Diabetes Study Group. Skyler JS, Rabinovitch A J DIABETES COMPLICAT 1992 6 2 77-88
37. 651256 Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. Silverstein J, Maclaren N, Riley W, Spillar R, Radjenovic D, Johnson S NEW ENGL J MED 1988 319 10 599-604
38. 651282 Modified anti-CD3 therapy in psoriatic arthritis: A phase I/II clinical trial. Utset TO, Auger JA, Peace D, Zivin RA, Xu D, Jolliffe L, Alegre ML, Bluestone JA, Clark MR J RHEUMATOL 2002 29 9 1907-1913
39. 652347 Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, hOKT3y1(Ala-Ala) in the treatment of acute renal allograft rejection. Woodle ES, Xu D, Zivin RA, Auger J, Charette J, O'Laughlin R, Peace D, Jolliffe LK, Haverty T, Bluestone JA, Thistlewaite JR Jr TRANSPLANTATION 1999 68 608-616
40. 651305 Anti-CD3 monoclonal antibody therapy. An approach toward optimization by in vitro analysis of new anti-CD3 antibodies. Woodle ES, Thistlethwaite JR, Jolliffe LK, Fucello AJ, Stuart FP, Bluestone JA TRANSPLANTATION 1991 52 2 361-368
41. 651307 T-cell activation and lymphokine production induced by antihuman CD3 monoclonal antibodies. Woodle ES, Thistlethwaite JR, Jolliffe LK, Ghobrial I, Fuccello AJ, Stuart FP, Bluestone JA TRANSPLANT PROC 1991 23 1 Pt 1 81-82
42. 651318 T lymphocyte activation following OKT3 treatment. Ellenhom JD, Woodle ES, Thistlethwaite JR, Bluestone JA CURR SURG 1990 47 6 458-459
43. 651319 Activation of human T cells in vivo following treatment of transplant recipients with OKT3. Ellenhom JD, Woodle ES, Ghobrial I, Thistlethwaite JR, Bluestone JA TRANSPLANTATION 1990 50 4 608-612
44. 651335 Naïve T cells are resistant to anergy induction by anti-CD3 antibodies. Andris F, Denanglaire S, de Mattia F, Urbain J, Leo O J IMMUNOL 2004 173 5 3201-3208
45. 651347 Effects of cyclosporine A on immune activation markers in patients with active psoriasis. Economidou J, Barkis J, Demetriou Z, Avgerinou G, Psarra K, Degiannis D, Vareltzidis A, Katsambas A DERMATOLOGY 1999 199 2 144-148
46. 651352 IA-2 antibody-negative status predicts remission and recovery of C-peptide levels in type 1 diabetic patients treated with cyclosporine. Christie MR, Molvig J, Hawkes CJ, Carstensen B, Mandrup-Poulsen T, Canadian-European Randomised Control Trial Group DAIBETES CARE 2002 25 7 1192-1197
47. 651819 Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Faulds D, Goa KL, Benfield P DRUGS 1993 45 6 953-1040
48. 651821 The effects of azathioprine, cyclosporine A and insulin on the in vitro lymphocyte-mediated cytotoxicity in type 1 diabetic patients. Horvath M, Varsanyi M, Bandi E, Balazsi I, Romics L EXP CLIN ENDOCRINOL 1992 100 3 90-94
49. 651822 Induction of tolerance to autoimmune diabetes with islet antigens. Herodl KC, Montag AG, Buckingham F J EXP MED 1992 176 4 1107-1114
50. 651892 Peptide-MHC class II dimmers as therapeutics to modulate antigen-specific T cell responses in autoimmune diabetes. Masteller EL, Warner MR, Ferlin W, Judkowski V, Wilson D, Glaichenhaus N, Bluestone JA J IMMUNOL 2003 171 10 5587-5595
51. 651893 Modulation of CD3 T cell function by soluble MHC II-peptide chimeras. Casares S, BonaCD, Brumeanu TD INT REV IMMUNOL 2001 20 5 547-573
52. 651903 Activation of natural killer T cells by α-galactosylceramide treatment prevents the onset and recurrence of autoimmune type 1 diabetes. Sharif S, Arreaza GA, Zucker P, Mi QS, Sondhi J, Naidenko OV, Kronenberg M, Koezuka Y, Delovitch TL, Gombert JM, Leite-de-Moraes M et al NAT MED 2001 7 9 1057-1062
53. 651914 Active tolerance induction and prevention of autoimmune diabetes by immunogene therapy using recombinant adenoassociated virus expressing glutamic acid decarboxylase 65 peptide GAD(500-585). Han G, Li Y, Wang J, Wang R, Chen G, Song L, Xu R, Yu M, Wu X, Qian J, Shen B J IMMUNOL 2005 174 8 4516-4524
54. 651916 DNA vaccination encoding glutamic acid decarboxylase can enhance insulitis and diabetes in correlation with a specific Th2/3 CD4 T cell response in non-obese diabetic mice. Gauvrit A, Debailleul M, Vu AT, Sai P, Bach JM CLIN EXP IMMUNOL 2004 137 2 253-262
55. 651917 Plasmid vaccination with insulin B chain prevents autoimmune diabetes in nonobese diabetic mice. Bot A, Smith D, Bot S, Hughes A, Wolfe T, Wang L, Woods C, von Herrath M J IMMUNOL 2001 167 5 2950-2955
56. 651918 Tolerance to islet antigens and prevention from diabetes induced by limited apoptosis of pancreatic β cells. Hugues S, Mougneau E, Ferlin W, Jeske D, Hofman P, Homann D, Beaudoin L, Schrike C, von Herrath M, Lehuen A, Glaichenhaus N IMMUNITY 2002 16 2 169-181
57. 651931 Clinical experience with the use of cyclosporine A in psoriasis. Results of a retrospective study. Ojeda R, Sanchez Regana M, Massana J, Oliete R, Umbert P J DERMATOL TREAT 2005 16 4 238-241
58. 651933 Prevalence and treatment of psoriasis in the United Kingdom: A population-based study. Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ ARCH DERMATOL 2005 141 12 1537-1541
59. 651937 Factors that regulate naturally occurring T regulatory cell-mediated suppression. Goleva E, Cardona ID, Ou LS, Leung DY J ALLERGY CLIN IMMUNOL 2005 116 5 1094-1100
60. 651938 Role of regulatory T cells in human diseases. Chatila TA J ALLERGY CLIN IMMUNOL 2005 116 5 949-959
61. 651940 CD3-specific antibodies restore self-tolerance. Mechanism and clinical applications. Chatenoud L CURR OPIN IMMUNOL 2005 17 6 632-637
62. 651943 Thymic regulatory T cells. Maggi E, Cosmi L, Liotta F, Romagnani P, Romagnani S, Annunziato F AUTOIMMUNITY REV 2005 4 579-586
63. 651949 The role of T cells in cutaneous autoimmune disease. Chow S, Rizzo C, Ravitskiy L, Sinha AA AUTOIMMUNITY 2005 38 4 303-317
64. 651954 Getting under the skin: The immunogenetics of psoriasis. Bowcock AM, Krueger JG NAT REV IMMUNOL 2005 5 9 699-711
65. 651957 The genetics of psoriasis and autoimmunity. Bowcock AM ANNU REV GENOMICS HUM GENET 2005 6 93-122
66. 651976 Psoriasis pathophysiology: Current concepts of pathogenesis. Krueger JG, Bowcock A ANN RHEUM DIS 2005 64 Suppl 2 30-36
67. 651977 Immune deviation strategies in the therapy of psoriasis. Ghoreschi K, Rocken M CURR DRUG TARGETS-INFLAMM ALLERGY 2004 3 2 193-198
68. 651978 Novel biologic therapies for psoriasis. Barry J, Kirby B EXPERT OPIN BIOL THER 2004 4 6 975-987
69. + regulatory T cell selection. Caton AJ, Cozzo C, Larkin J, 3rd, Lerman MA, Boesteanu A, Jordan MS ANN NY ACAD SCI 2004 1029 101-114
70. 651986 HLA-CW*0602 is a susceptibility factor in type 1 psoriasis, and evidence Ala-73 is increased in male type 1 psoriatics. Mallon E, Bunce M, Wojnarowska F, Wlesh K J INVEST DERMATOL 1997 109 183-186
71. 651988 Psoriasis and bacterial superantigens - formal or causal correlation? Boehncke WH TRENDS MICROBIOL 1996 4 12 485-489
72. 651991 Regulatory T cells in psoriasis. Kagen MH, McCormick TS, Cooper KD ERNST SCHERING RES FOUND WORKSHOP 2006 56 193-209
73. 651993 Cyclosporine nephrotoxicity in type 1 diabetic patients. A 7-year follow-up study. Parving HH, Tarnow L, Nielsen FS, Rossing P, Mandrup-Poulsen T, Osterby R, Nerup J DIABETES CARE 1999 22 3 478-483
74. 651996 Use of anti-CD3 monoclonal antibody to induce immune regulation in type 1 diabetes. Bisikirska BC, Herold KC ANN NY ACAD SCI 2004 1037 1-9
75. 652620 The effect of aglycosylation on the immunogenicity of a humanized therapeutic CD3 monoclonal antibody. Routledge EG, Falconer ME, Pope H, Lloyd IS, Waldmann H TRANSPLANTATION 1995 60 8 847-853
76. 652624 Viruses, cytokines, antigens, and autoimmunity. Gianani R, Sarvetnick N PROC NATL ACAD SCI USA 1996 93 6 2257-2259
77. + antigen-specific regulatory T cells. Bluestone JA, Tang Q PROC NATL ACAD SCI USA 2004 101 Suppl 2 14622-14626
78. 652627 Natural history of β-cell function in type 1 diabetes. Sherry NA, Tsai EB, Herold KC DIABETES 2005 54 Suppl 2 S32-S39
79. 652628 Failure to censor forbidden clones of CD4 T cells in autoimmune diabetes. Lesage S, Hartley SB, Akkaraju S, Wilson J, Townsend M, Goodnow CC J EXP MED 2002 196 9 1175-1188
80. 652631 Autoimmune destruction of pancreatic β cells. Yoon JW, Jun HS AM J THER 2005 12 6 580-591
81. 652632 Monogenic autoimmune diseases - lessons of self-tolerance. Ulmanen I, Halonen M, Ilmarinen T, Peltonen L CURR OPIN IMMUNOL 2005 176 609-615
82. 652635 Central tolerance: Learning self-control in the thymus. Hogquist KA, Baldwin TA, Jameson SC NAT REV IMMUNOL 2005 5 10 772-782
83. 652702 Activation-induced cell death in T cells and autoimmunity. Zhang J, Xu X, Liu Y CELL MOL IMMUNOL 2004 13 186-192
84. 657404 Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allograft. Cosimi AB, Colvin RB, Burton RC, Rubin RH, Goldstein G, Kung PC, Hansen WP, Delmonico FL, Russell PS N ENGL J MED 1981 305 6 308-314
85. 657630 Sparing of first dose effect of monovalent anti-CD3 antibody used in allograft rejection is associated with diminished release of pro-inflammatory cytokines. Abbs IC, Clark M, Waldmann H, Chatenoud L, Koffman CG, Sacks SH THER IMMUNOL 1994 1 6 325-331